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PURPOSE. To describe the phenotypic spectrum of retinal disease caused by the
c.2991þ1655A>G mutation in CEP290 and to compare disease severity between
homozygous and compound heterozygous patients.
METHODS. Medical records were reviewed for best-corrected visual acuity (BCVA), age of onset,
fundoscopy descriptions. Foveal outer nuclear layer (ONL) and ellipsoid zone (EZ) presence
was assessed using spectral-domain optical coherence tomography (SD-OCT). Differences
between compound heterozygous and homozygous patients were analyzed based on visual
performance and visual development.
RESULTS. A total of 66 patients were included. The majority of patients had either light
perception or no light perception. In the remaining group of 14 patients, median BCVA
was 20/195 Snellen (0.99 LogMAR; range 0.12–1.90) for the right eye, and 20/148 Snellen
(0.87 LogMAR; range 0.22–1.90) for the left. Homozygous patients tended to be more
likely to develop light perception compared to more severely affected compound
heterozygous patients (P ¼ 0.080) and are more likely to improve from no light
perception to light perception (P ¼ 0.022) before the age of 6 years. OCT data were
available in 12 patients, 11 of whom had retained foveal ONL and EZ integrity up to 48
years (median 23 years) of age.
CONCLUSIONS. Homozygous patients seem less severely affected compared to their compound-
heterozygous peers. Improvement of visual function may occur in the early years of life,
suggesting a time window for therapeutic intervention up to the approximate age of 17 years.
This period may be extended by an intact foveal ONL and EZ on OCT.
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Leber congenital amaurosis (LCA) is the most severe subtypeof inherited retinal disease and results in severe visual
impairment or blindness in the early years of adolescence,
affecting children from birth. LCA has an estimated prevalence
of 1 in 50,000 in Europe and North-America.1,2 While the
disease is characterized by early visual loss, amaurotic pupils,
nystagmus, and a very low or absent full-field electroretino-
gram,3,4 it is notoriously heterogeneous, both at the genotype
and phenotype level, and a wide range of genetic causes can
result in various degrees of disease severity.
A genetic cause may be found in up to 70% to 80% of all LCA
cases,5,6 and of the 23 genes7 known to be associated with this
disease, CEP290 is most frequently mutated, with up to 30% of
cases explained by pathogenic variants in this gene.8–10
The centrosomal protein 290 (CEP290) is a 290kDa protein
located primarily in the connecting cilium between the
photoreceptor inner and outer segments, and is involved in
cilium formation and intracellular protein trafficking.11,12
Mutations in this gene are a major cause of non-syndromic
Leber congenital amaurosis (LCA)13,14; however, cases of
retinitis pigmentosa (RP) and cone-rod dystrophy (CD) have
also been described.15,16 The most common retinal-disease-
causing variant in the CEP290 gene is the deep-intronic
c.2991þ1655A>G mutation, occurring in more than half of
CEP290-associated LCA cases.10,13 Interestingly, this variant
leads to the inclusion of a 128-bp pseudoexon to only a
proportion of CEP290 transcripts and thus can be considered a
hypomorphic variant.13 Mutations in CEP290 have also been
associated with systemic features, owing to the expression of
this gene in other tissues, including the kidney and the brain.
Consequently, non-ocular symptoms—including intellectual
disability and cystic renal disease—may be present in up to
22.2% of cases,17 often as part of Joubert or Senior-Loken
syndromes.12
Currently, no therapy exists for patients suffering CEP290-
associated retinal disease; however, trials exploring the efficacy
of antisense oligonucleotide-based genetic therapy—founded
on promising preclinical studies—are being undertaken.18–22
Insight into the natural disease course to evaluate patient
eligibility (more importantly, in determining the therapeutic
effect and the optimal time window for therapeutic interven-
tion) are vital for the further development and evaluation of
these therapies. A recent study on determining the best
efficacy outcome measures for clinical trials of CEP290-
associated LCA suggested minimal change in disease progres-
sion over a period of decades, thereby supporting the
impracticality of prospective natural history studies23 and
underlining the importance of proper retrospective character-
ization.
Relatively little is known about the natural disease course of
retinal disease associated with the c.2991þ1655A>G variant in
CEP290. In a cohort of 22 CEP290-related patients, a recent
study23 has suggested a difference in disease severity between
homozygous (n¼4) and compound heterozygous patients (n¼
18) in favor of homozygous patients. The considerable size of
the patient cohort in our study (n ¼ 66) has enabled us to
further investigate this genotype-phenotype correlation, add-
ing to our knowledge and understanding of the phenotypic
variability observed in patients carrying this deep-intronic
variant.
METHODS
Patient Selection
We identified 34 patients harboring at least one
c.2991þ1655A>G deep-intronic variant in the CEP290 gene
through the Dutch national retinal dystrophy database
(RD5000-Consortium).24 After contacting other centers in
Europe with an expertise in the care for retinal dystrophy
patients, we included 15 patients from the University Hospital
of Giessen, Germany, 11 patients from the University Hospital
of Ghent, Belgium, and 6 patients from the Righospitalet, at
Kennedy Center in Glostrup, Denmark. A total of 66 patients
were included in this study. Patient data from Belgium,
Germany, and Denmark were reviewed and anonymized by
the treating physician, and provided to the first author. Ethical
approval for the study was acquired before the start of data
collection, and all patients provided informed consent for the
use of their medical records by the study team. This study
adhered to the tenets of the Declaration of Helsinki.
Genetic Analysis
Genetic testing was performed using either the commercially
available LCA mutation arrayed primer extension microarray
(APEX) chip, version 2008 (Asper Biotech, Asper, Tartu, Estonia)
or by direct Sanger sequencing of all 53 coding exons and exon-
intron boundaries, and the deep-intronic region in intron 26 of
CEP290. Human Genome Variation Society (HGVS) mutation
nomenclature was used, with the A of the initiation codon ATG
as þ1.25 In the Danish LCA patients, the CEP290
c.2991þ1655A>G variant was assessed by mutation hotspot
screening utilizing the amplification-refractory mutation system
(ARMS). Detected variants were amplified, Sanger sequenced,
and finally validated with independent polymerase chain
reactions (PCR).26 The German cohort was analyzed using direct
Sanger sequencing, APEX, and next-generation sequencing.
Clinical Analysis
Medical records of all patients were reviewed, and clinical
ophthalmological data, including best-corrected visual acuity
(BCVA), age at onset, electroretinography (ERG) results, and
data concerning extraocular features and fundus appearance,
were extracted.
Visual acuity data were obtained in decimal scale and
transformed to the logarithm of the minimal angle of resolution
(LogMAR). To determine inter-eye symmetry, arbitrary values
for counting fingers (CF), hand movement (HM), light
perception (LP) and no light perception (NLP), were used.
These values were not used in analysis of baseline visual
performance or spontaneous visual improvement.
When available, visual acuity data were analyzed qualita-
tively over time in order to determine (1) the number of
patients who reached a visual acuity of LP or higher, (2) the
number of patients who progressed from LP or higher to NLP
and, lastly, (3) the number of patients who reportedly had NLP
at baseline, and improved to LP or higher. Single-visits were
excluded from this analysis, unless the visit occurred at a late
age and provided unambiguous information. Additionally,
multiple visits in short succession within the first year of life
were regarded as a single visit and were consequently excluded
from analysis.
Optical coherence tomography (OCT) images were ac-
quired using the Heidelberg HRA Spectralis system (Heidel-
berg, Germany) or the Stratus OCT (Carl Zeiss Meditec, Inc.,
Dublin, CA, USA). We evaluated OCT-images for the presence
of a structurally intact foveal outer nuclear layer (ONL) and
ellipsoid zone.
Statistical Analysis
Statistical analysis was performed using SPSS version 22.
Cross tabulation with the Fisher exact test was performed to
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determine whether there were statistically significant differ-
ences between homozygous and compound heterozygous
patients in terms of qualitative visual performance. We
investigated inter-eye symmetry at the moment of highest
asymmetry using Spearman’s rank correlation coefficient.
RESULTS
Genetic Analysis
Our cohort consisted of 20 patients homozygous for the
c.2991þ1655A>G variant, and 46 compound heterozygous
patients in combination with another pathogenic variant in
CEP290. A detailed overview of all encountered variants can
be found in Supplementary Table S1. One patient (10033)
was not genetically tested; however, he was presumed to
harbor the same compound heterozygous mutations as his
sibling (10025). Eight patients carried one of the recently
described hypomorphic variants15 p.(Arg151*) or
p.(Lys1575*) in conjunction with the deep-intronic variant
of interest. Nine novel variants were identified, only one of
which is of unknown pathogenicity (p.Asn1810His).
Retinal Phenotype
Baseline clinical data on all patients are summarized in
Supplementary Table S2. In general, the CEP290-associated
retinal disease phenotype is characterized by severe visual
impairment from birth (92.4%), marked hyperopia (68.1%), the
presence of nystagmus (77.2 %), non-recordable ffERG (57.1%),
sluggish or absent pupil reflexes (37.8%), and marked fundus
abnormalities (87.88%). In 13 patients, extraocular features
(EOF) were observed that may be related to a ciliopathy,
namely, delayed psychomotor development (5; 38.46%),
behavioral problems (4), mental retardation (1), nephronoph-
thisis (1), immotile spermatozoa (1), and epilepsy (1). Five
patients with EOF underwent magnetic resonance imaging
(MRI), and no abnormalities (specifically cerebellar vermis
hypoplasia) were detected.
The presence of nystagmus significantly complicated retinal
image acquisition. OCT images were available for only 12
patients, 11 of which showed an intact foveal ONL and
ellipsoid zone until the median age of 23 years (range 5–48
years), as depicted in Figure 1.
Fundus photographs were available for 14 patients, and
fundoscopy descriptions were available for 59 patients (a
summary of the fundus appearance can be found in
Supplementary Table S3). In general, the fundus appearance
progressed in a similar manner, starting with a normal or
blonde fundus aspect, later developing into a ‘‘salt & pepper’’-
like appearance with vessel attenuation and optic disc pallor,
peripheral and mid-peripheral pigment alterations, and bone
spicules. Three patients developed Coats-like vasculopathy,
and 11 patients developed cataract (three unilateral, eight
bilateral). One patient (10006) had ecstatic corneas that
hampered further ophthalmic examination.
Visual Acuity
Visual performance data were available for 63 patients (125
eyes). The median baseline BCVA was 0.99 LogMAR (14
eyes, range 0.12–1.90; 20/195 [range 20/26–20/1588]
Snellen) in the right, and 0.87 LogMAR (13 eyes, range
0.22–1.90; 20/148 [range 20/33–20/1588] Snellen) in the
left eye. Twenty-one patients had bilateral light perception,
two had CF (3 eyes), one saw hand movements only, and 25
had no perception of light.
The median age at baseline examination was 1.67 years
(range, 2 months–55 years). Twenty-five out of 66 (38%)
patients reportedly had no light perception at baseline
examination. Follow-up time and number of examinations
varied greatly among patients. The median follow-up time was
5 years (range, 0–58 years), and the median number of
examinations was 4 (range, 1–37). Spearman correlation
analysis was performed to determine inter-eye symmetry, and
no statistically significant difference was found (P ¼ 0.800).
Interestingly, a total of 4 patients (10001, 10010, 10016,
10017) showed spontaneous improvement of visual perfor-
mance up to the age of 17 years (median 15 years, range, 11–17
years), with a median gain of 0.25 LogMAR (range, 0.20–0.34
LogMAR), which is equivalent to 2 Early Treatment Diabetic
Retinopathy Study (ETDRS) chart lines. Patient 10001 im-
proved from 20/200 Snellen OS at age 9 to 20/125 Snellen OS
at age 16. Patient 10010 improved from LPþODS at the age of
6.5 years, to 20/125 in both eyes at age 10; the left eye
continued to improve to 20/80 at age 17 years. Patient 10016
improved from Snellen 20/200 OD and 20/125 OS at age 3.5
years, to 20/80 OD and 20/40 OS at age 11 years. Finally,
patient 10017 improved from 20/100 Snellen OD at age 7
years, to 20/40 OD at age 14 years. Figure 2 summarizes the
visual acuity course in these patients.
Differences in qualitative parameters for visual function
between homozygous and compound heterozygous patients
were investigated. Among the 18 homozygous patients with
visual performance data, 17 patients (94.4%) attained light
perception at some point during follow-up, compared with 28
out of 39 compound heterozygous patients (71.8%; P¼ 0.080;
Fig. 3A). Of the 44 patients with LP or higher BCVA, six (1
homozygous, 5 compound heterozygous) progressed to NLP in
at least one eye over a median period of 18 years (range, 1–44
years). There was no statistically significant difference between
groups in this regard (P ¼ 0.385; Fig. 3B).
When analyzing the improvement of no light perception to
light perception, we found that 4 out of 5 homozygous
patients, and 2 out of 13 compound heterozygous patients
who had no light perception at baseline, improved to light
perception or higher visual acuity (P ¼ 0.022) over a median
period of 4.9 years (range, 11 months–6 years). The remaining
homozygous and the 11 compound heterozygous patients did
not improve to light perception or higher VA. A summary of
these results can be found in Figure 3C.
Interestingly, three patients (10016, 10017, 10057) present-
ed with higher than usual visual acuity in the early years of life.
Siblings 10016 and 10017 had a Snellen (LogMAR) visual acuity
of 20/80 (0.60) in the right and 20/40 (0.30) in the left eye at
11 years, and 20/50 (0.40) in the right and 20/200 (1.00) in the
left eye at the age of 14 years, respectively. Patient 10057
attained a visual acuity of 20/63 (0.50) in both eyes by the age
of 11 years. Their clinical presentation was otherwise similar to
other patients.
While a classical severe LCA phenotype was present in the
majority of patients (64; 96.7%), two patients (10028, 10029)
presented with vastly different phenotypes. Patient 10028,
compound heterozygous for the c.2991þ1655A>G and the
c.4705-1G>T variant, had a relatively well-preserved visual
acuity of 20/50 (0.40) in both eyes by the age of 15 years and a
mildly flecked peripheral retina. An ERG revealed normal
scotopic, and lowered photopic (25%–30%) responses. The
clinical image resembled cone dystrophy.
Patient 10029, compound heterozygous for the
c.2991þ1655A>G and the c.5587-1G>C variant, had a
relatively well-preserved visual acuity of 20/100 in the right
and 20/50 in the left eye until the age of 28 years, after which
the right eye slowly declined, and became legally blind at age
34. The left eye started to slowly decline by the age of 33 years
Clinical Analysis of CEP290-Associated LCA IOVS j September 2018 j Vol. 59 j No. 11 j 4386
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/937492/ on 09/19/2018
and became legally blind by the age of 41 years. The
fundoscopic changes were consistent with the diagnosis of
RP, with bone spicules in the peripheral retina, and Coats-like
serous retinal detachment in the inferotemporal peripheral
retina in both eyes. The full-field ERG showed reduced
responses in both eyes.
DISCUSSION
In this study, we performed a large retrospective analysis of
visual impairment in LCA patients who are either homozygous
or compound heterozygous for the common deep-intronic
c.2991þ1655A>G mutation in CEP290. Evidently, despite
FIGURE 1. Optical coherence tomography (OCT) images of the right eyes of patients (ID indicated in the lower left corners, age in years in the
lower right), showing foveal outer nuclear layer and ellipsoid zone integrity in 11 patients (yellow triangles). Patient 10040 was the only exception,
as indicated by the red triangle. Zygosity is indicated in the upper right corner. H, homozygous; CH, compound heterozygous.
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being hypomorphic, this deep-intronic mutation results in a
severe retinal phenotype, affecting children from birth and
rendering them legally blind at a very young age. Our data
support the hypothesis suggesting homozygous patients suffer
a less severe phenotype compared with compound heterozy-
gous patients,23 as we found more favorable visual develop-
ment in homozygous patients when analyzed qualitatively.
However, the difference between groups was relatively small.
Interestingly, six patients’ vision seemed to have improved
before the age of 6 years, while having no light perception at
the time of diagnosis, suggesting the visual system may still
improve even when little functional CEP290 protein is present.
While an actual increase in visual acuity in these patients is up
for discussion, and visual acuity measurements are notorious
for inter-visit fluctuations,27 this phenomenon of transient
visual improvement has also been described in RPE65-
associated LCA and in CEP290.28–30 A possible explanation
for this spontaneous improvement in visual performance is the
physiological visual maturation, which is usually complete by
the age of 5.31–33 Alternatively, it could result from an
underestimation of the initial visual function due to inadequate
determination of light perception, owing to the practical
limitations of examining a young child. If this is indeed the
result of visual maturation, it is interesting that the period of
visual improvement extends well beyond the usually expected
5 years. Additionally, 4 patients with BCVA measurable by
FIGURE 2. Visual acuity course in patients with spontaneous improvement. LogMAR visual acuity in four patients with spontaneous improvement.
Note the variability in visual acuity in patient 10001. Lower values mean better visual acuity.
FIGURE 3. Visual outcome of homozygous compared to compound heterozygous patients. Bar graphs representing the percentage of total patients
within each group. (A) shows the fraction of patients who attained ‘‘light perception or higher visual acuity’’ at any point during follow-up. (B) The
fraction of patients who progressed from ‘‘light perception or higher visual acuity’’ to ‘‘no light perception,’’ and the fraction of patients who
developed ‘‘light perception or higher visual acuity’’ after previously having been observed with ‘‘no light perception’’ (C).
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ETDRS chart showed spontaneous improvement of visual
performance by up to 2 to 3 ETDRS lines, up to until the age of
17 years. It is still unclear whether this is true improvement of
visual function or a result of the aforementioned variability in
BCVA measurements.
Differences in genetic composition, delayed visual matura-
tion, and transient visual improvement are important features
not to be ignored when designing therapeutic efficacy trials. As
such, the expected therapeutic effect in compound heterozy-
gous patients might be lower than previously assumed, and the
therapeutic effect may be overestimated when tested in
patients younger than 17 years. That said, treating patients in
this stage might amplify the therapeutic effect, possibly
providing physicians with an optimal therapeutic time
window. Furthermore, while it is impossible to precisely
predict an individual patients’ clinical phenotype and disease
course, this information should be considered when discussing
a patient’s prognosis.
A clinical phase 1/2 trial investigating the safety and efficacy
of antisense oligonucleotide therapy has recently started,22 and
an important inclusion criterion is the required presence of the
macular outer nuclear layer (ONL) on OCT. It is likely that a
similar criterion will be applicable for other therapeutic studies
and possibly for future registered therapies. This underlines the
importance of OCT in these patients, despite the presence of
nystagmus that complicates the procedure. In our cohort, 11
patients had an intact foveal ONL and ellipsoid zone up to 48
years of age, in some cases even after visual acuity decreased to
LP levels. Although only 12 patients successfully underwent
OCT imaging, higher success rates have recently been
described, as using modern-day equipment increases viability
of OCT in these patients.23 Visual acuity will probably not be a
very good predictor of therapeutic efficacy, although in theory,
one might expect a rise in BCVA. This is due in part to the
inability to accurately determine BCVA at baseline using
standard procedures such as ETDRS charts, as well as the
uncertainty of their applicability even after visual improve-
ment. Additionally, while visual acuity, visual fields, and
contrast sensitivity are generally accepted measures of visual
performance, a direct measure of patient mobility is lacking. To
address this, multi-luminance mobility testing was developed
and validated by Chung et al.34 Recently, this methodology was
successfully implemented in clinical gene-therapy trials in
RPE65-associated retinal dystrophy.35
Our relatively large study cohort enabled us to investigate
the presence and nature of extraocular features associated with
the CEP290-associated disease phenotype. We found extra-
ocular features in 13 patients, bringing the prevalence in this
population to roughly 1 in 5 (19.7%), which is slightly lower
than the 22.2% previously reported in literature.17 Six of these
patients were homozygous, and 7 were compound heterozy-
gous with known pathogenic mutations. A clear link to a
certain type of second mutation could not be established, and
the factors that determine whether a patient expresses
extraocular features thus remain elusive. Additionally, it is
unclear whether some forms of developmental delay or mental
retardation may result from the severe visual impairment.
While homozygous patients do tend to have a less severe
retinal phenotype, the relative prevalence of extraocular
features in compound heterozygous patients is slightly higher,
although this difference was not statistically significant.
The c.2991þ1655A>G mutation results in aberrant splicing
of the CEP290 pre-mRNA, which leads to a reduction in
functional CEP290 protein of about 50% in either lymphoblas-
toid or fibroblast cells derived from LCA patients homozygous-
ly carrying the deep-intronic mutation in CEP290.13,18,19,21,36
Intriguingly, Parfitt et al.21 found that, whereas in induced
pluripotent stem cell (iPSC)-derived RPE cells, the amount of
residual correctly spliced CEP290 pre-mRNA was found to be
similar to LCA fibroblasts, only 10% to 20% residual wild-type
CEP290 transcript was present in iPSC-derived optic cup
photoreceptors. This optic cup model is especially interesting,
as it allows for observation of ciliary development in
photoreceptors in a controlled setting. Cilia incidence in LCA
optic cups was decreased at all stages of development
compared to control cups. Furthermore, during the first weeks
of optic cup development, the amount of correctly spliced
CEP290 pre-mRNA is roughly equivalent to what is observed in
fibroblast cells; however, the residual CEP290 transcript
diminished to around 10% to 20% after a few months of
differentiation. This most likely explains why patients with
LCA due to the deep-intronic mutation undergo normal retinal
development, sometimes with seemingly delayed visual matu-
ration yet, sooner or later, express profound loss of photore-
ceptor function.
The compound heterozygous patients in our cohort (nearly)
all harbored a loss-of-function mutation next to the deep-
intronic variant. This additional reduction in residual full-length
CEP290 protein might explain why the compound heterozy-
gous phenotype seems to be more severe. In contrast,
however, 8 patients in our cohort harbored a hypomorphic
variant in conjunction with the deep-intronic variant, and this
did not result in a milder phenotype in terms of visual
performance. Furthermore, 2 patients (10016, 10017) with a
remarkably high visual acuity were compound heterozygous
for another presumed loss-of-function mutation (p.Arg151*).
These results suggest that not all CEP290 mutations predicted
to result in premature termination of the CEP290 protein can
be considered full loss-of-function mutations. In addition, other
genetic or environmental factors may modify the disease
phenotype.
There are several limitations to this study. First, the
retrospective nature of the study leads to differences in
follow-up time and visit frequencies. Second, we included
patients from different centers, and visual acuity measurement
circumstances and imaging protocols varied among the
centers. Lastly, imaging was available only in a subset of
patients, which complicates an exhaustive analysis of the
retinal structure.
In summary, the deep-intronic c.2991þ1655A>G mutation
in CEP290 leads to a severe form of LCA, marked by severe
visual impairment from birth. Delayed visual maturation may
explain why some patients, more often homozygous for the
aforementioned mutation, still develop some degree of visual
function in the early years of life. Transient visual improvement
can occur, although this was present in a minority of patients.
Visual improvement after the age of 17 was not observed,
suggesting this might be an optimal time-window for
therapeutic intervention. Presence of a structurally intact
foveal outer nuclear layer and ellipsoid zone on OCT may be
useful to select optimal therapy candidates, and every effort
must be made to acquire foveal OCT images despite the
presence of nystagmus.
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